Pricing & Pharma Dialogue working group is determined to address the second goal of the Task Force, as stated in the Declaration of Intent:
‘Goal 2: Medicine prices should be sustainable and proportionate to real cost of research and development and added therapeutic value. In that respect an open, transparent and continuous dialogue with the pharmaceutical industry is needed. Knowledge and information must be shared internationally and co-operation must be sought after.’
Members of WG2 are conducting research acquiring list and acquisition prices of innovative cancer medicines and analysing various pricing policies/tendencies of national payers in Europe.
WG2 further works with the TF Chair and the ECL Secretariat on participation in a transparent and continuous dialogue with pharmaceutical industry.